Published in Haematologica on July 01, 2006
Iron-chelating therapy for transfusional iron overload. N Engl J Med (2011) 3.92
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol (2012) 1.45
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol (2009) 1.40
Cardiac iron across different transfusion-dependent diseases. Blood Rev (2008) 1.37
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Liver iron content determination by magnetic resonance imaging. World J Gastroenterol (2010) 1.21
An update on iron chelation therapy. Blood Transfus (2012) 1.19
A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci (2013) 1.11
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol (2011) 0.99
Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol (2010) 0.98
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol (2008) 0.97
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol (2008) 0.96
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
Activity of deferasirox in Mucorales: influences of species and exogenous iron. Antimicrob Agents Chemother (2010) 0.94
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag (2007) 0.91
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology (2010) 0.88
Iron chelation therapy in myelodysplastic syndromes. Adv Hematol (2010) 0.87
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One (2013) 0.85
Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals (2010) 0.84
Recent advances in β-thalassemias. Pediatr Rep (2011) 0.82
Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One (2013) 0.82
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica (2012) 0.81
Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag (2009) 0.80
Pharmacology of iron transport. Annu Rev Pharmacol Toxicol (2012) 0.79
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med (2015) 0.78
The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Ann Hematol (2015) 0.78
The revolution of myelodysplastic syndromes. Ther Adv Hematol (2011) 0.76
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective. Pharmacoeconomics (2013) 0.76
Management of the thalassemias. Cold Spring Harb Perspect Med (2013) 0.76
Targeting angiogenesis as a therapeutic means to reinforce osteocyte survival and prevent nonunions in the aftermath of radiotherapy. Head Neck (2014) 0.76
Iron chelation therapy in thalassemia syndromes. Mediterr J Hematol Infect Dis (2009) 0.76
The oral chelator deferasirox--a new perspective for patients with iron overload. Haematologica (2006) 0.75
The role of galenic innovation in improving treatment compliance and persistence: three case studies. Clinicoecon Outcomes Res (2011) 0.75
Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major. Pak J Med Sci (2015) 0.75
Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment. Oncotarget (2017) 0.75
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol (2003) 3.38
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 3.07
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Beta-thalassemia. Genet Med (2010) 2.24
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica (2008) 2.12
Purging iron from the heart. Br J Haematol (2004) 2.07
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica (2003) 1.94
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol (2007) 1.74
KLF1 gene mutations cause borderline HbA(2). Blood (2011) 1.71
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene. Am J Hematol (2010) 1.60
Feasibility and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in children. J Pediatr Gastroenterol Nutr (2012) 1.55
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am (2002) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol (2011) 1.45
Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42
Optimal management of β thalassaemia intermedia. Br J Haematol (2011) 1.41
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Thrombosis and sickle cell disease. Semin Thromb Hemost (2011) 1.32
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica (2010) 1.31
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica (2004) 1.30
How I treat transfusional iron overload. Blood (2012) 1.29
Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med (2008) 1.27
The homozygosity index (HI) approach reveals high allele frequency for Wilson disease in the Sardinian population. Eur J Hum Genet (2013) 1.27
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica (2008) 1.24
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica (2011) 1.23
Pathophysiology of beta thalassaemia. Pediatr Endocrinol Rev (2011) 1.22
Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol (2004) 1.22
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem (2003) 1.21
An update on iron chelation therapy. Blood Transfus (2012) 1.19
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res (2003) 1.19
Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol (2003) 1.18
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica (2008) 1.18
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica (2008) 1.16
High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol (2009) 1.16
International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging (2010) 1.14
Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence (2013) 1.13
Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica (2008) 1.13
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma (2004) 1.12
A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol (2011) 1.12
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
Retrospective study of 111 cases of congenital diaphragmatic hernia treated with early high-frequency oscillatory ventilation and presurgical stabilization. J Pediatr Surg (2007) 1.11
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10